Literature DB >> 7815335

Reversal of nerve ligation-induced allodynia by spinal alpha-2 adrenoceptor agonists.

T L Yaksh1, J W Pogrel, Y W Lee, S R Chaplan.   

Abstract

After nerve injury, a sympathetically dependent allodynia may be observed. Spinal alpha-2 agonists inhibit preganglionic neurons. The nature of the effect of alpha-2 agonists on allodynia induced by L5 and L6 nerve ligation (Chung model) was thus examined. Rats were implanted with spinal intrathecal catheters directed at the upper lumbar (L1-L2) or the lower cervical (C5-C6) spinal levels. After nerve injury, rats displayed a tactile allodynia (mean withdrawal thresholds, < 2.3 g). Lumbar intrathecal injection of alpha-2, but not alpha-1 or an opiate agonist, resulted in a dose-dependent reversal of the allodynia, with the ordering of activity (ED50 in micrograms in parentheses) being dexmedetomidine (0.9) > oxymetazoline (14) = guanfacine (17) = 5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline (19) = 2-(2,6-diethylphenylamino)-2-imidazoline (21) = clonidine (22) > morphine (> 30) = methoxamine (> 30 micrograms). The effects of clonidine and 2-(2,6-diethylphenylamino)-2-imidazoline were reversed by the intrathecal injection of yohimbine. At equivalent doses, clonidine delivered systemically, i.c.v. by chronic ventricular guides, or at the level of the cervical spinal cord, produced substantially less antiallodynic action. These results jointly suggest that the sites of the antiallodynic action of spinal alpha-2 agonists are located at the level of the spinal preganglionic neurons and correspond to their ability to diminish preganglionic sympathetic outflow. The failure of morphine to exert an antiallodynic action reflects the fact that 1) opiates act presynaptically on small primary afferents and the allodynia is mediated by large afferent input and 2) opiates, unlike alpha-2 agonists do not have an effect on autonomic outflow.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815335

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

1.  Perioperative infusion of dexmedetomidine at a high dose reduces postoperative analgesic requirements: a randomized control trial.

Authors:  Norimasa Ohtani; Yutaka Yasui; Daisuke Watanabe; Mari Kitamura; Kazuhiro Shoji; Eiji Masaki
Journal:  J Anesth       Date:  2011-09-28       Impact factor: 2.078

2.  Contribution of alpha(2) receptor subtypes to nerve injury-induced pain and its regulation by dexmedetomidine.

Authors:  A B Malmberg; L R Hedley; J R Jasper; J C Hunter; A I Basbaum
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 3.  Pharmacologic treatment of neuropathic pain.

Authors:  M S Wallace
Journal:  Curr Pain Headache Rep       Date:  2001-04

Review 4.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

5.  Intrathecal clonidine in the neonatal rat: dose-dependent analgesia and evaluation of spinal apoptosis and toxicity.

Authors:  Suellen M Walker; Marjorie Grafe; Tony L Yaksh
Journal:  Anesth Analg       Date:  2012-03-30       Impact factor: 5.108

Review 6.  Modulation of pain transmission by G-protein-coupled receptors.

Authors:  Hui-Lin Pan; Zi-Zhen Wu; Hong-Yi Zhou; Shao-Rui Chen; Hong-Mei Zhang; De-Pei Li
Journal:  Pharmacol Ther       Date:  2007-09-22       Impact factor: 12.310

7.  Potentiation of spinal alpha(2)-adrenoceptor analgesia in rats deficient in TRPV1-expressing afferent neurons.

Authors:  Shao-Rui Chen; Hao-Min Pan; Timothy E Richardson; Hui-Lin Pan
Journal:  Neuropharmacology       Date:  2007-03-24       Impact factor: 5.250

Review 8.  Behavioral models of pain states evoked by physical injury to the peripheral nerve.

Authors:  Linda S Sorkin; Tony L Yaksh
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

9.  Neuropathic and inflammatory pain are modulated by tuberoinfundibular peptide of 39 residues.

Authors:  Eugene L Dimitrov; Jonathan Kuo; Kenji Kohno; Ted B Usdin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

Review 10.  Pain in terminally ill patients: guidelines for pharmacological management.

Authors:  Jay R Thomas; Charles F von Gunten
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.